The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 7, 2012, Pages 1220-1230

  Rocca, B ^a   Santilli, F ^b   Pitocco, D ^a   Mucci, L ^a   Petrucci, G ^a   Vitacolonna, E ^b   Lattanzio, S ^b   Mattoscio, D ^b   Zaccardi, F ^a   Liani, R ^b   Vazzana, N ^b   Del Ponte, A ^b   Ferrante, E ^b   Martini, F ^a   Cardillo, C ^a   Morosetti, R ^a   Mirabella, M ^a   Ghirlanda, G ^a   Davi G ^b   Patrono, C ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

Aspirin; Diabetes; Platelets; Thromboxane

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CARDIOASPIRIN; CYCLOOXYGENASE 1; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INCRETIN; INSULIN; INTERLEUKIN 6; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROTON PUMP INHIBITOR; SULFONYLUREA; THROMBOXANE B2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; DIABETIC PATIENT; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; INSULIN TREATMENT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOCYTE; THROMBOCYTE VOLUME;

AGED; ASPIRIN; BLOOD PLATELETS; CASE-CONTROL STUDIES; CYCLOOXYGENASE 1; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; THROMBOXANE B2;

EID: 84863430537     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04723.x     Document Type: Article

References (41)

1. th Edition). Chest 2008; 133: 199S-233S.
2. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, Gachet C, Montalescot G, Jennings LK, Kereiakes D, Sibbing D, Trenk D, van Werkum JW, Paganelli F, Price MJ, Waksman R. Consensus and future directions on the definition of high on treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919-33.
3. Rocca B, Patrono C. Determinants of the interindividual variability in response to antiplatelet drugs. J Thromb Haemost 2005; 3: 1597-602.
4. 2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment. Eur Heart J 2009; 30: 1279-86.
5. DiChiara J, Bliden KP, Tantry US, Hamed MS, Antonino MJ, Suarez TA, Bailon O, Singla A, Gurbel PA. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients. An analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes 2007; 56: 3014-9.
6. Evangelista V, De Berardis G, Totani L, Avanzini F, Giorda CB, Brero L, Levantesi G, Marelli G, Pupillo M, Iacuitti G, Pozzoli G, di Summa P, Nada E, de Simone G, Dell'Elba G, Amore C, Manarini S, Pecce R, Maione A, Tognoni G, et al. Persistent platelet activation in patients with type 2 diabetes treated with low doses of aspirin. J Thromb Haemost 2007; 5: 2197-203.
7. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, Lee R, Bancroft J, MacEwan S, Shepherd J, Macfarlane P, Morris A, Jung R, Kelly C, Connacher A, Peden N, Jamieson A, Matthews D, Leese G, McKnight J, et al. Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337: 1030-6.
8. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y, for the JPAD Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes. A randomized controlled trial. JAMA 2008; 300: 2134-41.
9. De Berardis G, Sacco M, Strippoli GFM, Pellegrini F, Graziano G, Tognoni G, Nicolucci A. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009; 339: b4531.
10. PignoneM MJ, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, Rosenson RS, Williams CD, Wilson PW, Kirkman MS. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation 2010; 121: 2694-701.
11. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69: 1366-72.
12. Patrono C, Ciabattoni G, Patrignani P, Pugliese F, Filabozzi P, Catella F, Davì G, Forni L. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 1985; 72: 1177-84.
13. Santilli F, Rocca B, De Cristofaro R, Lattanzio S, Pietrangelo L, Habib A, Pettinella C, Recchiuti A, Ferrante E, Ciabattoni G, Davì G, Patrono C. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays. J Am Coll Cardiol 2009; 53: 667-77.
14. Dragani A, Pascale S, Recchiuti A, Mattoscio D, Lattanzio S, Petrucci G, Mucci L, Ferrante E, Habib A, Ranelletti FO, Ciabattoni G, Davì G, Patrono C, Rocca B. The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. Blood 2010; 115: 1054-61.
15. Pascale S, Petrucci G, Dragani A, Habib A, Zaccardi F, Pagliaccia F, Pocaterra D, Ragazzoni E, Rolandi G, Rocca B, Patrono C. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood 2012; 119: 3565-603.
16. Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353: 2373-83.
17. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006; 29: S43-S48.
18. 2 production in healthy subjects. Thromb Res 1980; 17: 317-27.
19. Pradelles P, Grassi J, Maclouf J. Enzyme immunoassays of eicosanoids using acetylcholine esterase as label: an alternative to radioimmunoassay. Anal Chem 1985; 57: 1170-3.
20. 2 in man. Biochim Biophys Acta 1989; 992: 66-70.
21. Barsam SJ, Psaila B, Forestier M, Page LK, Sloane PA, Geyer JT, Villarica GO, Ruisi MM, Gernsheimer TB, Beer JH, Bussel JB. Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia. Blood 2011; 117: 5723-32.
22. Perneby C, Wallén NH, Rooney C, Fitzgerald D, Hjemdahl P. Dose- and time-dependent antiplatelet effects of aspirin. Thromb Haemost 2006; 95: 652-8.
23. Henry P, Vermillet A, Boval B, Guyetand C, Petroni T, Dillinger JG, Sideris G, Sollier CB, Drouet L. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost 2011; 105: 336-44.
24. Lordkipanidzé M, Pharand C, Schampaert E, Palisaitis DA, Diodati JG. Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease. Int J Cardiol 2011; 150: 39-44.
25. Maree AO, Curtin RJ, Dooley M, Conroy RM, Crean P, Cox D, Fitzgerald DJ. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol 2005; 46: 1258-63.
26. Frelinger AL, Li Y, Linden MD, Fox ML, Christie DJ, Furman MI, Michelson AD. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation 2009; 120: 2586-2596.
27. Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984; 311: 1206-11.
28. Burch JW, Stanford N, Majerus PW. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 1978; 61: 314-9.
29. Ault KA, Rinder HM, Mitchell J, Carmody MB, Vary CP, Hillman RS. The significance of platelets with increased RNA content (reticulated platelets). A measure of the rate of thrombopoiesis. Am J Clin Pathol 1992; 98: 637-46.
30. Spectre G, Arnetz L, Ostenson CG, Brismar K, Li N, Hjemdahl P. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. Thromb Haemost 2011; 106: 491-9.
31. 2+-ATPase expression in diabetes: a novel signature of abnormal megakaryocytopoiesis. J Thromb Haemost 2007; 5: 2127-35.
32. Brown AS, Hong Y, de Belder A, Beacon H, Beeso J, Sherwood R, Edmonds M, Martin JF, Erusalimsky JD. Megakaryocyte ploidy and platelet changes in human diabetes and atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 802-7.
33. Tschöpe D, Schwippert B, Schettler B, Kiesel U, Rothe H, Roesen P, Gries FA. Increased GPIIB/IIIA expression and altered DNA-ploidy pattern in megakaryocytes of diabetic BB-rats. Eur J Clin Invest 1992; 22: 591-8.
34. Smith JP, Haddad EV, Taylor MB, Oram D, Blakemore D, Chen Q, Boutaud O, Oates J. Suboptimal inhibition of platelet cyclooxygenase-1 by aspirin in metabolic syndrome. Hypertension 2012; 59: 719-725.
35. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010; 49: 71-87.
36. Addad F, Chakroun T, Elalamy I, Abderazek F, Chouchene S, Dridi Z, Gerotziafas GT, Hatmi M, Hassine M, Gamra H. Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes. Int J Hematol 2010; 92: 296-301.
37. Capodanno D, Patel A, Dharmashankar K, Ferreiro JL, Ueno M, Kodali M, Tomasello SD, Capranzano P, Seecheran N, Darlington A, Tello-Montoliu A, Desai B, Bass TA, Angiolillo DJ. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Interv 2011; 4: 180-7.
38. A Study of Cardiovascular Events in Diabetes (ASCEND). (Accessed March 23, 2010).
39. De Berardis G, Sacco M, Evangelista V, Filippi A, Giorda CB, Tognoni G, Valentini U, Nicolucci A. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trials in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials 2007; 8: 21.
40. Nelson MR, Reid CM, Ames D, Beilin LJ, Donnan GA, Gibbs P, Johnston CI, Krum H, Storey E, Tonkin A, Wolfe R, Woods R, McNeil JJ. Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: results from ASPirin in Reducing Events in the Elderly (ASPREE) pilot study. Med J Aust 2008; 189: 105-9.
41. Aspirin to reduce risk of initial vascular events (ARRIVE). Accessed 15 November 2011.